Skip to main content

Table 7 FDA-approved therapeutic drugs for melanoma and other skin cancers

From: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Drug (brand name)

Sponsor

Properties

Indication

Approval date

Review

Vemurafenib (Zelboraf)

Roche

BRAF inhibitor

BRAF-positive unresectable or metastatic melanoma

08/17/2011

P, O

Dabrafenib mesylate (Tafinlar)

Novartis

Kinase inhibitor with activity against BRAFV600E/D/K, wild-type BRAF and other kinases

Unresectable or metastatic melanoma with BRAFV600E mutation

05/29/2013

S, O

Encorafenib (Braftovi)

Array BioPharma

BRAF inhibitor

BRAF-mutated melanoma

06/27/2018

S, O

Trametinib DMSO (Mekinist)

Novartis

MEK1/2 inhibitor

Unresectable or metastatic melanoma with BRAFV600E mutation

05/29/2013

S, O

Cobimetinib fumarate (Cotellic)

Genentech

MEK inhibitor

Melanoma with BRAFV600E/K mutations

11/10/2015

P, O

Binimetinib (Mektovi)

Array BioPharma

MEK inhibitor

BRAF-mutated melanoma

06/27/2018

S, O

Ipilimumab (Yervoy)

Bristol-Myers Squibb

CTLA4‑directed mAb

Unresectable or metastatic melanoma

03/25/2011

P, O

Pembrolizumab (Keytruda)

Merck

PD1-directed mAb

Metastatic melanoma

09/04/2014

P, O

Nivolumab (Opdivo)

Bristol-Myers Squibb

PD1-directed mAb

Unresectable or metastatic melanoma

12/22/2014

P, O

Vismodegib (Erivedge)

Genentech

Smoothened inhibitor

Advanced basal cell carcinoma

01/30/2012

P

Sonidegib phosphate (Odomzo)

Sun Pharma

Smoothened inhibitor

Basal cell carcinoma

07/24/2015

S

Avelumab (Bavencio)

Emd Serono

PDL1-directed mAb

Merkel cell carcinoma

03/23/2017

P, O

Cemiplimab (Libtayo)

Regeneron

PD1-directed mAb

Cutaneous squamous cell carcinoma

09/28/2018

P

  1. CTLA4 Cytotoxic T lymphocyte antigen 4; MEK MAPK/ERK kinase; O Orphan; P Priority; PD1 Programmed death receptor-1; PDL1 Programmed death-ligand 1; S Standard